Nurix Therapeutics
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
Corporate information
- Company entity
- Nurix Therapeutics, Inc.
- Headquarters / principal office
- Brisbane, CaliforniaSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Ownership / capital status
- Publicly tradedPublicly traded (NASDAQ: NRIX) ↗
- Official corporate reference
- https://www.nurixtx.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-10-27 · Post-IPO registered offering · $250 million gross proceeds ↗
Completed offering with a verifiable amount identified in this review; registered offering capacity is not treated as actual financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.